J Dig Cancer Res.
2022 Dec;10(2):82-91. 10.52927/jdcr.2022.10.2.82.
Drug Discovery Platform Using Organoids
- Affiliations
-
- 1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
- 2Laboratory of Cell Biology, Cancer Research Institute, Seoul National University, Seoul, Korea
- 3Korean Cell Line Bank, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- 4Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2536425
- DOI: http://doi.org/10.52927/jdcr.2022.10.2.82
Abstract
- Gastrointestinal cancer accounts for one-third of the overall cancer occurrence worldwide. Pancreatic ductal adenocarcinoma (PDAC) is a type of gastrointestinal cancer that is known to be one of the most fatal among all cancer types, with a 5-year survival rate of less than 8%. Chemotherapy combined with surgical resection is its probable curative option. However, surgery is accessible for only 10–15% of patients diagnosed with PDAC. Organoids show self-organizing capacities and resemble the original tissue in terms of morphology and function. Organoids can also be cultured with high effectiveness from tumor tissues derived from each patient, making them an extremely fitting model for translational uses and improving personalized cancer medicine. Enhancing drug screening platforms is necessary to apply personalized medicinebased organoids in clinical settings.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Current Challenges Associated with the Use of Human Induced Pluripotent Stem Cell-Derived Organoids in Regenerative Medicine
- Preclinical investigation of patient-derived cervical cancer organoids for precision medicine
- Novel Drug Screening Platform: Tumor Organoid
- Region Specific Brain Organoids to Study Neurodevelopmental Disorders
- Enhancing generation efficiency of liver organoids in a collagen scaffold using human chemically derived hepatic progenitors
